Novel use of combination therapeutic plasma exchange and rituximab in the treatment of nivolumab‐induced bullous pemphigoid

Ridpath, Alyson; Rzepka, Polina V.; Shearer, Sabrina M.; Scrape, Scott; Olencki, Thomas; Kaffenberger, Benjamin H.

doi:10.1111/ijd.13970

Cited by 30 publications

(20 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other prednisolone sparing immune modulating agents include Cyclosporine, Rituximab ( 28 , 30 , 31 ), intravenous immunoglobulin ( 32 ), Cyclophosphamide ( 33 ), and plasmapheresis ( 34 , 35 ). Some of these treatments can be used in combination ( 36 ).…”

Section: Treatment Of Bullous Pemphigoidmentioning

confidence: 99%

Comorbidities and Treatment Strategies in Bullous Pemphigoid: An Appraisal of the Existing Litterature

2018

View full text Add to dashboard Cite

Bullous Pemphigoid is an autoimmune skin blistering disease. It is caused by deposition of auto antibodies along the dermal-epidermal border leading to inflammation. The antibodies are directed against anchoring filaments in the epidermis, but these antigens are also present in the neurological tissues and this has led to speculation of an association between multiple sclerosis and bullous pemphigoid. Additionally recent epidemiological studies have pointed at an increased risk of cardio-vascualr diseases and an increased moratality among the patients with bullous pemphigoid. In this mini review we present the recent findings in this area and as well as the treatment strategies when comorbidities are taken into consideration.

show abstract

Section: Treatment Of Bullous Pemphigoidmentioning

confidence: 99%

Comorbidities and Treatment Strategies in Bullous Pemphigoid: An Appraisal of the Existing Litterature

2018

View full text Add to dashboard Cite

show abstract

“…To our knowledge, BP is a rare cutaneous irAE and there are 16 previous cases of BP developing during nivolumab-therapy [3][4][5][6][7] . In oncologic patients, BP may be idiopathic, paraneoplastic or related to medication, including cancer therapy.…”

Section: Discussionmentioning

confidence: 99%

Bullous pemphigoid induced by nivolumab in a patient with malignant melanoma

Adachi

Yokoyama²,

Yamagami³

et al. 2020

Trends Immunother

View full text Add to dashboard Cite

Immune checkpoint inhibitors, such as nivolumab, have been recognized that the enhanced immune responses often lead to immune-related adverse events (irAEs) in various organs. Although cutaneous toxicity is one of the most common irAEs, bullous pemphigoid (BP) with immune checkpoint inhibitors is rare. Herein, the authors report a case of BP in a patient of the metastatic malignant melanoma of the brain under the treatment of nivolumab. It is notable that this case showed the clear correlation between the status of using of nivolumab and serum levels of anti-BP180 antibody. In addition, the skin eruptions in the case were mainly pruritic erosive or crusted papules and these clinical features may be the clinical characteristics of BP induced by nivolumab.

show abstract

“…The majority of patients also received methotrexate, doxycycline with or without nicotinamide, or omalizumab either concurrently with the steroids or alone afterward as maintenance. Rituximab has also been utilized in the literature as a steroid‐sparing agent (Ridpath et al, Sowerby, Dewan, Granter, Gandhi, & LeBoeuf, ).…”

Section: Discussionmentioning

confidence: 99%

A case of atezolizumab‐induced photodistributed bullous pemphigoid

Leavitt

Holland

2019

Dermatologic Therapy

View full text Add to dashboard Cite

Immunotherapy has revolutionized cancer therapy in recent years but is associated with unique immunologically mediated adverse effects. Immunotherapy‐induced bullous pemphigoid (BP) is an uncommon but established reaction that portends significant management implications as in most instances systemic treatment is required. We report a case of immunotherapy‐associated BP in a marked photodistribution, highlighting the diverse clinical presentations of this eruption.

show abstract

Novel use of combination therapeutic plasma exchange and rituximab in the treatment of nivolumab‐induced bullous pemphigoid

Cited by 30 publications

References 6 publications

Comorbidities and Treatment Strategies in Bullous Pemphigoid: An Appraisal of the Existing Litterature

Comorbidities and Treatment Strategies in Bullous Pemphigoid: An Appraisal of the Existing Litterature

Bullous pemphigoid induced by nivolumab in a patient with malignant melanoma

A case of atezolizumab‐induced photodistributed bullous pemphigoid

Contact Info

Product

Resources

About